Stay updated on Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page.

Latest updates to the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check19 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check27 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference1.0%
- Check34 days agoChange DetectedThe web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.SummaryDifference0.2%
- Check41 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.1%
- Check48 days agoChange DetectedA service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference0.9%
Stay in the know with updates to Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page.